Genclis
Biotechnology company developing RNA-derived therapeutics for drug discovery and development
Highlights
- New on EvolcAdded 2026-10-30
About Genclis
Genclis develops therapeutics based on Transcription Infidelity, a mechanism that creates gaps in mRNA and produces proteins with specific immunological properties. Its platform focuses on alternate RNA-derived therapeutics.
The company is based in Vandœuvre-les-Nancy, France, and was founded in 2006. Its drug-development fields include veterinary and human allergy, severe COVID-19, type I diabetes and Lou Gehrig’s disease.
Product: A biotechnology platform and drug-development programs based on Transcription Infidelity and alternate RNA-derived therapeutics.
Jobs at Genclis
No open positions listed right now.
More biotech & pharma companies
Generare Bioscience
Microbial chemistry libraries and screenable molecules for pharma and biotech drug discovery programsNew on EvolcRemote-friendlyGENOMINES
Grows nickel-accumulating plants on low-grade soils to produce battery-grade nickel for critical metal supply chainsGenoscreen
Genomics, sequencing and bioinformatics services for academic and industrial research teamsNew on EvolcGenoskin
Ex vivo human skin models, mast cells and research services for pharmaceutical, biotech, cosmetics and medical-device developersNew on EvolcGenoway
Preclinical mouse, rat and cell line models with custom model design for pharma and academic researchersNew on EvolcGensensor
Automated bioprocess sampling robot and AI analytics for biologics makers in biomedicine, agri-food and cosmeticsYoung companyNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Google reCAPTCHA
- LiteSpeed
- WooCommerce
- WordPress
- jQuery